Ingrid Teigland Akay, Md Mba

Mitral Regurgitation is the third most common cardiovascular disease that occurs when there is backward flow of blood across the mitral valve. It is highly prevalent, debilitating for patients, and deadly if untreated. The market is expected to be larger than the TAVR market, currently a $6B market. The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible. Therefore, the CardioMech device can potentially reduce the need for open-heart surgery and may lessen the need for watchful waiting in younger and healthier patients. Caution: Investigational device. Limited by law to investigational use.

Alex Therapeutics is a digital health company that partners with pharma to support people with treatment and disease-related mental health challenges through clinically validated companion apps. Alex Therapeutics specializes in oncology and rare diseases, which are typically accompanied by complex treatment regimes and emotional distress.

Neuro Event Labs develop scalable solutions for registering data about patient’s epilepsy seizures by using video and other sensors; combined with smart analytics helping medical staff to use the data efficiently; as well as tools for patients to take an active role in the care taking process. Neuro Event Labs started in 2015 as a spin-off of Intopalo.

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers. Oncoinvent – Innovations for better cancer care.

Forskningsrådet skal gi næring til nye ideer, gjøre grensesprengende forskning og radikal innovasjon mulig. Vi jobber for et samfunn der forskning blir skapt, brukt og delt, og der vi bidrar til omstilling og et mer bærekraftig samfunn. På vegne av regjeringen investerer vi 11,4 milliarder kroner i året i forsknings- og innovasjonsprosjekter. Oppgaven vår er å sikre at de beste forsknings- og innovasjonsprosjektene får finansering.

Nisonic is developing an advanced ultrasound technology to measure the pressure in the brain (intracranial pressure) in a harmless and cost-effective way. Several indications can affect the intracranial pressure, including head trauma, stroke, meningitis and other central nervous system infections, brain tumours, etc. Today the only accurate measurement method is by invasive insertion of a sensor directly into the cranium, with the risks of bleeding, infections and damage to the brain tissue.

Gentian Diagnostics – a global medical diagnostics company – develops and manufactures high quality, in vitro diagnostic (IVD) reagents for a wide range of clinical chemistry analysers. Our product lines of laboratory tests, for diverse medical conditions, improve accuracy and provide faster results, for both human and veterinary healthcare. Gentian Diagnostics serves the global market for human and veterinary medical diagnostic tests via our OEM partners and key distributors. The Gentian HQ and production facility is in Moss, Norway. We also have a representative office in China and the distribution subsidiaries: Gentian USA, Inc. and Gentian Diagnostics AB (Sweden). Our interdisciplinary and international teams work on global solutions to ensure #DiagnosticEfficiency. Gentian products: PLASMA CALPROTECTIN – CYSTATIN C – CANINE CRP Connect with us: Web: www.gentian.com E-mail: marketing@gentian.com Facebook: facebook.com/GentianDiagnostics Twitter: twitter.com/GentianDiagnost Twitter: twitter.com/Cystatin_C

Mitral Regurgitation is the third most common cardiovascular disease that occurs when there is backward flow of blood across the mitral valve. It is highly prevalent, debilitating for patients, and deadly if untreated. The market is expected to be larger than the TAVR market, currently a $6B market. The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible. Therefore, the CardioMech device can potentially reduce the need for open-heart surgery and may lessen the need for watchful waiting in younger and healthier patients. Caution: Investigational device. Limited by law to investigational use.

Alex Therapeutics is a digital health company that partners with pharma to support people with treatment and disease-related mental health challenges through clinically validated companion apps. Alex Therapeutics specializes in oncology and rare diseases, which are typically accompanied by complex treatment regimes and emotional distress.

Neuro Event Labs develop scalable solutions for registering data about patient’s epilepsy seizures by using video and other sensors; combined with smart analytics helping medical staff to use the data efficiently; as well as tools for patients to take an active role in the care taking process. Neuro Event Labs started in 2015 as a spin-off of Intopalo.

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers. Oncoinvent – Innovations for better cancer care.

Forskningsrådet skal gi næring til nye ideer, gjøre grensesprengende forskning og radikal innovasjon mulig. Vi jobber for et samfunn der forskning blir skapt, brukt og delt, og der vi bidrar til omstilling og et mer bærekraftig samfunn. På vegne av regjeringen investerer vi 11,4 milliarder kroner i året i forsknings- og innovasjonsprosjekter. Oppgaven vår er å sikre at de beste forsknings- og innovasjonsprosjektene får finansering.